Serial Cerebrospinal Fluid Sampling Reveals Trajectories of Potential Synaptic Biomarkers in Early Stages of Alzheimer’s Disease
Authors:
Open Access
- 20 August 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 100 (s1) , S103-S114
Abstract
Background: Synaptic dysfunction is closely associated with cognitive function in Alzheimer’s disease (AD), and is present already in an early stage of the disease. Objective: Using serial cerebrospinal fluid (CSF) sampling, we aimed to investigate slopes of CSF synaptic proteins, and their relation with cognition along the AD continuum. Methods: We included subjects with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) (n = 50 amyloid-β+ [A +], n = 50 A–) and 50 patients with AD dementia from the Amsterdam dementia cohort, with CSF at two time points (median[IQR] 2.1[1.4–2.7] years). We analyzed 17 synaptic proteins and neurofilament light (NfL). Using linear mixed models we assessed trajectories of protein levels, and associations with cognitive decline (repeated Mini-Mental State Examination). We used Cox regression models to assess predictive value of protein levels for progression to AD dementia. Results: At baseline most proteins showed increased levels in AD dementia compared to the other groups. In contrast NPTX2 levels were lower in AD dementia. Higher baseline levels of SNAP25, β-syn, and 14-3-3 proteins were associated with faster cognitive decline (St.B[SE] –0.27[0.12] to –0.61[0.12]). Longitudinal analyses showed that SYT1 and NPTX levels decreased over time in AD dementia (st.B[SE] –0.10[0.04] to –0.15[0.05]) and SCD/MCI-A+ (St.B[SE] –0.07[0.03] to –0.12[0.03]), but not in SCD/MCI-A- (pinteraction < 0.05). Increase over time in NfL levels was associated with faster cognitive decline in AD dementia (St.B[SE] –1.75[0.58]), but not in the other groups (pinteraction < 0.05). Conclusions: CSF synaptic proteins showed different slopes over time, suggesting complex synaptic dynamics. High levels of especially SNAP-25 may have value for prediction of cognitive decline in early AD stages, while increase in NfL over time correlates better with cognitive decline in later stages.Keywords
This publication has 47 references indexed in Scilit:
- Alzheimer's disease drug development pipeline: 2023Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023
- Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disordersAlzheimer's & Dementia, 2022
- Relationship of serum beta‐synuclein with blood biomarkers and brain atrophyAlzheimer's & Dementia, 2022
- A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non‐converter Alzheimer's disease subjects with consideration for their amyloid beta statusAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022
- Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's diseaseAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in NeurologyJAMA Neurology, 2019
- Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseJAMA Neurology, 2015
- Biobanking of CSF: International standardization to optimize biomarker developmentClinical Biochemistry, 2014
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011